
    
      A multi-centre, double-blind, placebo-controlled, 20-week parallel group extension study to
      the VIR-NCHR-01 protocol (ITV study). The purpose of the extension study is to assess the
      safety and virological effects of a therapeutic HIV vaccine strategy in HIV-1 infected adults
      currently enrolled in the ITV study after cessation of antiretroviral therapy. Two active
      candidate vaccines will be studied in this trial: The active treatment arms will receive
      recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens or HIV gag-pol antigens and
      interferon-gamma (IFN-y) in diluent. Vaccines will be delivered by intramuscular injection.
    
  